Non-Anticoagulant Heparins as Heparanase Inhibitors

Area of Science:

• Biochemistry
• Enzymology
• Pharmacology

Background:

• Heparanase is an endo-β-D-glucuronidase enzyme that degrades heparan sulfate.
• Heparanase overexpression is implicated in cancer, inflammation, diabetes, atherosclerosis, and nephropathies.
• Heparan sulfate proteoglycans are crucial components of mammalian cells.

Purpose of the Study:

• To review the discovery and characterization of heparanase.
• To discuss non-anticoagulant heparins as inhibitors of heparanase.
• To highlight the development and clinical evaluation of heparanase inhibitors.

Main Methods:

• Structure-activity relationship studies of heparin derivatives.
• Advanced chemical-physical analytical methods for polysaccharide characterization.
• Development of screening assays for heparanase inhibitors and in vivo evaluation.

Main Results:

• Identification of novel non-anticoagulant heparin derivatives with anti-heparanase activity.
• Characterization and sequencing of polysaccharide chains using new analytical techniques.
• Successful preclinical and early clinical evaluation of heparanase inhibitors.

Conclusions:

• Non-anticoagulant heparins represent a promising therapeutic strategy targeting heparanase.
• Ongoing clinical trials are investigating these inhibitors for oncology and other diseases.
• Further research is warranted to fully elucidate the therapeutic potential of heparanase inhibition.